Form 8-K

8-K — InMed Pharmaceuticals Inc.

Accession: 0001213900-26-101492

Filed: 2026-09-18

Period: 2026-09-16

CIK: 0001728328

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Item: Other Events

Item: Financial Statements and Exhibits

Documents

8-K — ea0305769-8k_inmed.htm (Primary)

EX-99.1 — PRESS RELEASE (ea030576901ex99-1.htm)

GRAPHIC (ea030576901_ex99-1img1.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — CURRENT REPORT

8-K (Primary)

Filename: ea0305769-8k_inmed.htm · Sequence: 1

false

0001728328

2026-09-16

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date

of Report (Date of earliest event reported): September 16, 2026

INMED PHARMACEUTICALS INC.

(Exact name of registrant as specified in its charter)

British Columbia

001-39685

98-1428279

(State or other jurisdiction

(Commission File Number)

(IRS Employer

of incorporation)

Identification No.)

c/o Norton Rose Fulbright Canada LLP

Suite 1800 – 510 West Georgia Street

Vancouver, British Columbia, Canada V6B 0M3

(Address of principal executive offices) (Zip Code)

Registrant’s

telephone number, including area code: (604) 669-7207

Not

Applicable

(Former name or former address, if changed since last report)

Check

the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under

any of the following provisions:

☐ Written

communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting

material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities

registered pursuant to Section 12(b) of the Act:

Title

of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Shares, no par value

INM

The Nasdaq Stock Market LLC

Indicate

by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405

of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b -2 of this chapter).

Emerging

growth company ☐

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item

3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On September 16, 2026, InMed Pharmaceuticals Inc. (the "Company")

received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") notifying it that it

is not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires companies listed on The Nasdaq Capital Market to maintain a minimum

of $2,500,000 in shareholders’ equity for continued listing. In its Annual Report on Form 10-K for the fiscal year ended June 30,

2026, the Company reported shareholders’ equity of $1,075,007, and, as a result, the Company does not currently satisfy Nasdaq Listing

Rule 5550(b)(1).

The decline in the Company’s shareholders’

equity is attributable largely to transaction-related expenses accrued in connection with the Company’s previously announced Agreement

and Plan of Merger and Reorganization dated May 19, 2026 (as amended, the “Merger Agreement”) entered into with Mentari Therapeutics,

Inc. (“Mentari”), pursuant to which, among other things, the Company will merge with Mentari (the “Merger”).

Following the Merger, and as a result of the

previously disclosed Mentari pre-closing financing, the combined company is expected to receive aggregate gross proceeds of approximately

$490.0 million (which includes $50.0 million of proceeds previously received by Mentari from the issuance of its convertible notes and

accrued interest on such notes). Accordingly, the Company expects that closing of the transactions contemplated by the Merger Agreement

will result in the Company regaining compliance with The Nasdaq Capital Market’s minimum shareholders’ equity requirement.

The Company’s closing share price as of

September 18, 2026 represents an increase of approximately $0.68 (~99.8%) compared to the closing price immediately prior to the initial

announcement of the Merger Agreement.

The transactions contemplated by the Merger Agreement

are expected to close in the fourth quarter of 2026, subject to, among other things, shareholder approval.

For more information related to the Merger, including

the pre-closing financing transaction, please see the Company’s Form S-4 Registration Statement filed on July 2, 2026, as amended

by Amendment No. 1, filed with the U.S. Securities and Exchange Commission (the “SEC”) on September 9, 2026, including the

documents and filings incorporated by reference therein.

The decline in the Company’s shareholders’

equity is also attributable to costs associated with the wind-down of its wholly owned subsidiary, BayMedica, LLC, increased general and

administrative expenses, impairment charges related to the Company’s intangible assets, and continued operating losses.

The notice has no immediate impact on the listing

of the Company's common shares, which will continue to trade on The Nasdaq Capital Market subject to the Company's continued compliance

with the other listing requirements of The Nasdaq Capital Market. The common shares of the Company will continue to trade under the symbol

"INM". The notice provides the Company 45 calendar days, or until November 2, 2026, to submit a plan to regain compliance. If

the plan is accepted, the Company can be granted up to 180 calendar days from September 16, 2026 (or until March 15, 2027) to evidence

compliance. There can be no assurance that the Company will be able to regain compliance with all applicable continued listing requirements

or that its plan will be accepted by the Nasdaq staff. In the event the plan is not accepted by the Nasdaq staff, or in the event the

plan is accepted but the Company fails to regain compliance within the plan period, the Company would have the right to a hearing before

an independent panel pursuant to the procedures set forth in the applicable Nasdaq Listing Rules. However, there can be no assurance that,

if the Company does appeal any delisting determination by Nasdaq to a panel, such appeal would be successful.

The Company intends to take all reasonable measures

available to regain compliance under the Nasdaq Listing Rules and remain listed on Nasdaq, including continuing to pursue the consummation

of the Merger. The Company intends to submit the compliance plan by the Nasdaq deadline. However, there can be no assurance that the Company’s

compliance plan will be accepted by Nasdaq, that it will be able to regain compliance with Nasdaq Listing Rule 5550(b)(1), maintain compliance

with the other Nasdaq listing requirements or be successful in appealing any delisting determination.

Item 8.01 Other Events.

On September 18, 2026, the Company issued a press

release announcing its receipt of the written notice from the Listing Qualifications Department of Nasdaq described above. A copy of the

press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein. The press release contains forward-looking statements

and includes cautionary statements identifying important factors that could cause actual results to differ materially from those in the

forward-looking statements.

Cautionary Note Regarding Forward-Looking Information:

This Current Report on Form 8-K contains "forward-looking

information" and "forward-looking statements" (collectively, "forward-looking information") within the meaning

of applicable securities laws. Forward-looking information is based on management's current expectations and beliefs and is subject to

a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.

Without limiting the foregoing, forward-looking information in this Current Report on Form 8-K includes, but is not limited to, the Company’s

plan to regain compliance with the minimum shareholders’ equity requirement under Nasdaq Listing Rule 5550(b)(1), the above-noted

180-day extension that Nasdaq may grant the Company, any potential notification from Nasdaq that the Company’s shares may be subject

to delisting, the continued listing of the Company’s securities and the ability to trade the Company’s securities on Nasdaq

after the above-noted 180-day extension period, and the outcome of any appeal by the Company to a Nasdaq hearings panel, as well as the

expected closing of, and benefits of, the transactions contemplated by the Merger Agreement, the expected aggregate gross proceeds to

the combined company of approximately $490 million from the Mentari pre-closing financing, and the Company’s belief that the closing

of the transactions contemplated by the Merger Agreement will result in the Company regaining compliance with Nasdaq’s minimum shareholders’

equity requirement.

With respect to the forward-looking information

contained in this Current Report on Form 8-K, it is important to note that actual outcomes and the Company’s actual results could

differ materially from those in such forward-looking information. Actual results could differ from those projected in any forward-looking

information due to numerous factors. Such factors include, among others: uncertainty whether the Company can prepare a plan to regain

compliance or whether a plan, if any, to regain compliance submitted to Nasdaq will be accepted or if accepted, whether the Company will

regain compliance with the applicable minimum shareholders’ equity rule within the timelines required by Nasdaq, failing which,

the Company’s securities will be delisted by Nasdaq; uncertainty whether the Company would appeal any delisting notice or whether

any such appeal would be successful, failing which, the Company’s securities would be delisted by Nasdaq; the risk that delisting

of the Company’s securities may have a material adverse effect on the Company’s share liquidity and trading price and on the

Company’s ability to obtain financing and continue its business; uncertainty as to whether the transactions contemplated by the

Merger Agreement will close on the expected timeline or at all; uncertainty whether the expected benefits of the transactions contemplated

by the Merger Agreement will be realized; uncertainty whether the expected aggregate gross proceeds from the Mentari pre-closing financing

will be received or whether the closing of the transactions contemplated by the Merger Agreement will result in the Company regaining

compliance with Nasdaq’s minimum shareholders’ equity requirement; and the risk of changes in business strategy or plans.

Additionally, there are known and unknown risk

factors which could cause the Company’s actual results, performance or achievements to be materially different from any future results,

performance or achievements expressed or implied by the forward-looking information contained herein. A complete discussion of the risks

and uncertainties facing the Company’s stand-alone business is disclosed in the Company’s most recent Annual Report on Form

10-K and other filings with the SEC on www.sec.gov and the Canadian securities regulators on SEDAR+ at www.sedarplus.com.

All forward-looking information herein is qualified

in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information

or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results,

events or developments, except as required by law.

No Offer or Solicitation

This Current Report on Form 8-K is for informational

purposes only and does not constitute an offer to sell, or the solicitation of an offer to buy, any securities, or the solicitation of

any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be

unlawful prior to registration or qualification under the securities laws of any such jurisdiction. Without limiting the foregoing, this

Current Report on Form 8-K does not constitute an offer to sell, or the solicitation of an offer to buy, any securities in connection

with any private placement or other financing by Mentari or the Company. Any such securities have not been and will not be registered

under the Securities Act of 1933 (the “Securities Act”) or any state securities laws and may not be offered or sold in the

United States absent registration or an applicable exemption from registration. No offering of securities shall be made except by means

of a prospectus meeting the requirements of Section 10 of the Securities Act or an applicable exemption therefrom.

Important Additional Information About the

Merger and Where to Find It

In connection with the transactions contemplated

by the Merger Agreement, the Company has filed with the SEC a registration statement on Form S-4 that includes a preliminary proxy statement/prospectus

of the Company and a management information circular and will file other relevant documents with the SEC and applicable Canadian securities

regulators. The Form S-4 has not yet become effective. After the Form S-4 is declared effective, the Company will mail a definitive proxy

statement/prospectus and management information circular to its shareholders and to Mentari's stockholders. INVESTORS AND SECURITYHOLDERS

OF THE COMPANY AND MENTARI ARE URGED TO READ THE FORM S-4, THE PROXY STATEMENT/PROSPECTUS AND MANAGEMENT INFORMATION CIRCULAR (INCLUDING

ALL AMENDMENTS AND SUPPLEMENTS) AND ALL OTHER RELEVANT DOCUMENTS FILED OR TO BE FILED WITH THE SEC AND CANADIAN SECURITIES REGULATORS,

CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE, BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT THE COMPANY,

MENTARI, THE MERGER AND RELATED MATTERS. Investors and securityholders may obtain free copies of these documents (when available) through

the SEC's website at www.sec.gov, on SEDAR+ at www.sedarplus.com, or from the Company at www.inmedpharma.com/investors.

Participants in the Solicitation

The Company, Mentari and their respective directors

and executive officers may be deemed to be participants in the solicitation of proxies from the Company's shareholders and Mentari's stockholders

in connection with the proposed Merger. Information regarding the Company's directors and executive officers and a description of their

direct and indirect interests, by security holdings or otherwise, is set forth in the Company's most recent Annual Report on Form 10-K

and its other filings with the SEC and on SEDAR+. Additional information regarding the participants and their interests is or will be

contained in the proxy statement/prospectus and management information circular and other relevant materials filed or to be filed with

the SEC and Canadian securities regulators. These documents may be obtained free of charge as described above.

Item 9.01 Financial Statements and Exhibits.

Exhibit

No.

Description

99.1

Press Release

104

Cover Page Interactive Data File (embedded within the Inline XBRL document and included as Exhibit 104)

SIGNATURES

Pursuant

to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by

the undersigned hereunto duly authorized.

INMED PHARMACEUTICALS INC.

Date: September 18, 2026

By:

/s/ Eric A. Adams

Eric

A. Adams

President & CEO

EX-99.1 — PRESS RELEASE

EX-99.1

Filename: ea030576901ex99-1.htm · Sequence: 2

Exhibit 99.1

Nasdaq: INM

c/o Norton Rose Fulbright Canada LLP

Suite 1800-510 West Georgia St.

Vancouver, BC, Canada V6B 0M3

Tel: +1.604.669.7207

Email: info@inmedpharma.com

www.inmedpharma.com

InMed Pharmaceuticals Receives Nasdaq Notification

Regarding Minimum Stockholders’ Equity Compliance

Vancouver, BC – September 18, 2026 – InMed Pharmaceuticals

Inc. (“InMed” or the “Company”) (Nasdaq: INM), a pharmaceutical company focused on developing

a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, announces that it has received a

letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”), notifying the Company

that the shareholders’ equity of $1,075,007 as reported in the Company’s Annual Report on Form 10-K for the fiscal year ended

June 30, 2026, was below the minimum shareholders’ equity of $2,500,000 required for continued listing on The Nasdaq Capital Market

as set forth in Nasdaq Listing Rule 5550(b)(1).

The decline in the Company’s shareholders’

equity is attributable largely to transaction-related expenses accrued in connection with the Company’s previously announced Agreement

and Plan of Merger and Reorganization dated May 19, 2026 (as amended, the “Merger Agreement”) entered into with Mentari

Therapeutics, Inc. (“Mentari”), pursuant to which, among other things, the Company will merge with Mentari (the “Merger”).

Following the Merger, and as a result of the

previously disclosed Mentari pre-closing financing, the combined company is expected to receive aggregate gross proceeds of approximately

$490.0 million (which includes $50.0 million of proceeds previously received by Mentari from the issuance of its convertible notes and

accrued interest on such notes). Accordingly, the Company expects that closing of the transactions contemplated by the Merger Agreement

will result in the Company regaining compliance with Nasdaq’s minimum shareholders’ equity requirement.

InMed’s closing share price as of September

18, 2026 represents an increase of approximately $0.68 (~99.8%) compared to the closing price immediately prior to the initial announcement

of the Merger Agreement.

The transactions contemplated by the Merger Agreement

are expected to close in the fourth quarter of 2026, subject to, among other things, shareholder approval.

The decline in the Company’s shareholders’

equity is also attributable to costs associated with the wind-down of its wholly owned subsidiary, BayMedica, LLC, increased general

and administrative expenses, impairment charges related to the Company’s intangible assets, and continued operating losses.

Nasdaq has provided the Company with 45 calendar

days to submit a plan to regain compliance with the minimum shareholders’ equity standard. If the Company’s plan is accepted,

Nasdaq may grant an extension of up to 180 calendar days from the date of the letter to evidence compliance with the minimum shareholders’

equity standard. In the event the Company does not evidence compliance with the minimum shareholders’ equity requirement during

the relevant period, Nasdaq may notify the Company that its common shares are subject to delisting. At such time, the Company may appeal

such determination to a Nasdaq Hearings Panel (the “Panel”), and it is expected that the Company’s securities

would continue to be listed and available to trade on Nasdaq at least pending the completion of the appeal process. In such event, there

can be no assurance that any such appeal would be successful or that the Company would be able to evidence compliance with the terms

of any extension that may be granted by the Panel.

About InMed

InMed Pharmaceuticals is a pharmaceutical company

focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. InMed’s pipeline consists

of three separate programs in the treatment of Alzheimer’s, ocular and dermatological indications. For more information, visit www.inmedpharma.com.

Investor Contact:

Colin Clancy

Vice President, Investor Relations

and Corporate Communications

T: +1.604.416.0999

ir@inmedpharma.com

Cautionary Note Regarding Forward-Looking Information:

This news release contains "forward-looking

information" and "forward-looking statements" (collectively, "forward-looking information") within the meaning

of applicable securities laws. Forward-looking information is based on management's current expectations and beliefs and is subject to

a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.

Without limiting the foregoing, forward-looking information in this news release includes, but is not limited to, the Company’s

plan to regain compliance with the minimum shareholders’ equity requirement, the above-noted 180-day extension that Nasdaq may grant

the Company, any potential notification from Nasdaq that the Company’s shares may be subject to delisting, the continued listing

of the Company’s securities and the ability to trade the Company’s securities on Nasdaq after the above-noted 180-day extension

period, and the outcome of any appeal by the Company to the Panel, as well as the expected closing of, and benefits of, the transactions

contemplated by the Merger Agreement, the expected aggregate gross proceeds to the combined company of approximately $490 million from

the Mentari pre-closing financing and the Company’s belief that the closing of the transactions contemplated by the Merger Agreement

will result in the Company regaining compliance with Nasdaq’s minimum shareholders’ equity requirement.

With respect to the forward-looking information contained in this news

release, it is important to note that actual outcomes and the Company’s actual results could differ materially from those in such

forward-looking information. Actual results could differ from those projected in any forward-looking information due to numerous factors.

Such factors include, among others: uncertainty whether the Company can prepare a plan to regain compliance or whether a plan, if any,

to regain compliance submitted to Nasdaq will be accepted or, if accepted, whether the Company will regain compliance with the applicable

minimum shareholders’ equity rule within the timelines required by Nasdaq, failing which, the Company’s securities will be

delisted by Nasdaq; uncertainty whether the Company would appeal any delisting notice or whether any such appeal would be successful,

failing which, the Company’s securities would be delisted by Nasdaq; the risk that delisting of the Company’s securities may

have a material adverse effect on the Company’s share liquidity and trading price and on the Company’s ability to obtain financing

and continue its business; uncertainty as to whether the transactions contemplated by the Merger Agreement will close on the expected

timeline or at all; uncertainty whether the expected benefits of the transactions contemplated by the Merger Agreement will be realized;

uncertainty whether the expected aggregate gross proceeds from the Mentari pre-closing financing will be received or whether the closing

of the transactions contemplated by the Merger Agreement will result in the Company regaining compliance with Nasdaq’s minimum shareholders’

equity requirement; and the risk of changes in business strategy or plans. Additionally, there are known and unknown risk factors which

could cause InMed's actual results, performance or achievements to be materially different from any future results, performance or achievements

expressed or implied by the forward-looking information contained herein. A complete discussion of the risks and uncertainties facing

InMed’s stand-alone business is disclosed in InMed’s latest Annual Report on Form 10-K, and other filings with the Securities

and Exchange Commission (the “SEC”) at www.sec.gov and the Canadian securities regulators on SEDAR+ at www.sedarplus.com.

All forward-looking information herein is qualified

in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information

or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results,

events or developments, except as required by law.

No Offer or Solicitation

This communication is

for informational purposes only and does not constitute an offer to sell, or the solicitation of an offer to buy, any securities, or the

solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation

or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. Without limiting

the foregoing, this communication does not constitute an offer to sell, or the solicitation of an offer to buy, any securities in connection

with any private placement or other financing by Mentari or InMed. Any such securities have not been and will not be registered under

the Securities Act of 1933 (the “Securities Act”) or any state securities laws and may not be offered or sold in the

United States absent registration or an applicable exemption from registration. No offering of securities shall be made except by means

of a prospectus meeting the requirements of Section 10 of the Securities Act or an applicable exemption therefrom.

Important Additional

Information About the Merger and Where to Find It

In connection with the

transactions contemplated by the Merger Agreement, InMed has filed with the SEC a registration statement on Form S-4 that includes a preliminary

proxy statement/prospectus of InMed and a management information circular and will file other relevant documents with the SEC and applicable

Canadian securities regulators. The Form S-4 has not yet become effective. After the Form S-4 is declared effective, InMed will mail a

definitive proxy statement/prospectus and management information circular to its shareholders and to Mentari’s stockholders. INVESTORS

AND SECURITYHOLDERS OF INMED AND MENTARI ARE URGED TO READ THE FORM S-4, THE PROXY STATEMENT/PROSPECTUS AND MANAGEMENT INFORMATION CIRCULAR

(INCLUDING ALL AMENDMENTS AND SUPPLEMENTS) AND ALL OTHER RELEVANT DOCUMENTS FILED OR TO BE FILED WITH THE SEC AND CANADIAN SECURITIES

REGULATORS, CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE, BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT

INMED, MENTARI, THE MERGER AND RELATED MATTERS. Investors and securityholders may obtain free copies of these documents (when available)

through the SEC’s website at www.sec.gov, on SEDAR+ at www.sedarplus.com,

or from InMed at www.inmedpharma.com/investors.

Participants in the Solicitation

InMed, Mentari and their

respective directors and executive officers may be deemed to be participants in the solicitation of proxies from InMed’s shareholders

and Mentari’s stockholders in connection with the proposed Merger. Information regarding InMed’s directors and executive officers and

a description of their direct and indirect interests, by security holdings or otherwise, is set forth in InMed’s most recent Annual Report

on Form 10-K and its other filings with the SEC and on SEDAR+. Additional information regarding the participants and their interests is

or will be contained in the proxy statement/prospectus and management information circular and other relevant materials filed or to be

filed with the SEC and Canadian securities regulators. These documents may be obtained free of charge as described above.

GRAPHIC

Filename: ea030576901_ex99-1img1.jpg · Sequence: 3

Binary file (12774 bytes)

Download ea030576901_ex99-1img1.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.3

Cover

Sep. 16, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Sep. 16, 2026

Entity File Number

001-39685

Entity Registrant Name

INMED PHARMACEUTICALS INC.

Entity Central Index Key

0001728328

Entity Tax Identification Number

98-1428279

Entity Incorporation, State or Country Code

Entity Address, Address Line One

c/o Norton Rose Fulbright Canada LLP

Entity Address, Address Line Two

Suite 1800 – 510 West Georgia Street

Entity Address, City or Town

Vancouver

Entity Address, Country

Entity Address, Postal Zip Code

V6B 0M3

City Area Code

604

Local Phone Number

669-7207

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Shares, no par value

Trading Symbol

INM

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

ISO 3166-1 alpha-2 country code.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCountry

Namespace Prefix:

dei_

Data Type:

dei:countryCodeItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration